Washington

The Health Care Authority issued a final rule changing the time frame in which manufacturers must report new drugs marketed in the state and incorporate the prescription drug pricing transparency program’s nondisclosure agreement.

Also in Washington, effective July 1, 2021, Apple Health (Medicaid) which is administered by the Health Care Authority (agency) will implement changes to the State Maximum Allowable Costs (SMAC) list for the fee-for-service (FFS) Prescription Drug Program. Please view the MAC memo for more details.  Additionally, the full SMAC list can be found on the agency’s Provider billing guides and fee schedules website under the Prescription Drug Program and applies to claims billed FFS.

Also in Washington, effective for claims with dates of service on and after July 1, 2021, Apple Health (Medicaid) updated the pharmacy Expedited Authorization (EA) List. On the Provider Billing Guides and Fee Schedules Page, scroll to Prescription Drug Program Billing Guides to access.

Also in Washington, the Office of the Insurance Commissioner issued a notice extending the Emergency Order 20-01 requiring health insurers to waive copays and deductibles for COVID-19 testing. The order also requires insurers to allow a one-time early refill for prescription drugs, suspends any prior authorization requirement for treatment or testing of COVID-19, and allows enrollees to be treated by out-of-network providers within a reasonable distance at no additional cost when the insurer does not have enough in-network medical providers.

Lastly in Washington, the Department of Health issued a final rule effective June 18, clarifying dispensers must submit information to the prescription monitoring program as soon as possible, but no later than one business day. The rule also removes the requirement that a facility or entity be a trading partner with the state’s health information exchange to have access to the prescription monitoring program.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2021-06-11T15:08:06-04:00June 11, 2021|Washington|

Alabama

The Board of Health published a notice to announce the removal of the opioid antagonist samidorphan from Schedule II of the Controlled Substances List attached to regulations under AAC 420-7-2. The action is a response to the federal Drug Enforcement Administration removing the substance on April 19. The action is effective May 19, 2021.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2021-06-04T13:13:17-04:00June 4, 2021|Alabama|

Alaska

HB 145, modernizing the pharmacy practice statutes, passed both the House Labor and Commerce Committee and the House Health and Social Services Committee earlier this year and will carry over and remain active for consideration as 2021-2022 continues next year.  The bill defines patient care activities pharmacists may provide and empowers the Board of Pharmacy to regulate those services; empowers the Board of Pharmacy to more effectively regulate pharmacy support staff; and supports reimbursement for health care services by defining those services and including pharmacists in the state’s provider anti-discrimination statute.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-06-04T13:12:14-04:00June 4, 2021|Alaska|

Arkansas

On May 30, Gov. Asa Hutchinson (R) officially ended the public health emergency which has been in place since March 11, 2020.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2021-06-04T13:11:31-04:00June 4, 2021|Arkansas|

California

The Medi-Cal Rx Monthly Bulletin dated June 1, 2021, includes a summary of previously shared updates and serves as a reminder of upcoming changes, deadlines, and opportunities as outlined below:

  • Changes to the Contract Drugs List, Effective June 1, 2021
  • Medi-Cal Rx Training Information
  • UAC Registration Troubleshooting
  • Medi-Cal Rx UAC Application Roles
  • Provider Registration and FAQs
  • Medi-Cal Rx Transition and Resources Training

Also in California, the Department of Health Care Services (DHCS) delayed the planned Go-Live date for Medi-Cal Rx.  On May 28, 2021, DHCS posted an update for providers and will continue to communicate additional information as it becomes available.

Also in California, the Medi-Cal Update Bulletin 992 – May 2021 includes updates to the List of Enteral Nutrition Products, effective for dates of service on or after July 1, 2021, and various provider manual updates. See bulletin for additional information.

Also in California, on May 27, 2021, the DUR Board Meeting Minutes for February 23, 2021, were posted to the DUR: Board Meetings page of the Medi-Cal website.

Also in California, as the June 30 end of the fiscal year approaches, the Board of Pharmacy expects a delay in processing payments for license renewals submitted by mail during the last week of June and the first week of July and provided guidance to licensees.

Lastly in California, the Office of Administrative Law approved regulations regarding automated drug delivery systems and off-site storage of records that take effect July 1, 2021.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-06-04T13:09:29-04:00June 4, 2021|California|

Colorado

The State Board of Pharmacy announced a virtual Stakeholder Meeting on June 14th to receive feedback on Notice, Draft Rules, SB21-011, SB21-094, SB21-122, and SB21-123.

  • Potential rule changes related to Colorado Senate Bill 21-011 (Concerning responsibilities of a pharmacist related to opiate antagonists);
  • Potential rule changes related to Colorado Senate Bill 21-094 (Concerning implementing recommendations contained in the 2020 sunset report that make changes regarding the practice of professions regulated by the Board);
  • Implementing Colorado Senate Bill 21-122 (Concerning the bulk purchase of opiate antagonists according to a standing order);
  • Implementing Colorado Senate Bill 21-123 (Concerning expanding the Canadian prescription drug importation program); and
  • New and revised rules are recommended by the Board and stakeholders to provide clarity and a general cleanup of the rules.

To register in advance, go to Webinar Registration. Written comments should be sent by June 10th to – dora_dpo_rulemaking@state.co.us.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-06-04T13:08:26-04:00June 4, 2021|Colorado|

Indiana

The Office of the Secretary of Family and Social Services issued a notice of a proposal to reimburse COVID-19 vaccine administration and monoclonal antibody treatment at the Medicare rate, effective July 1, 2021. Comments are due June 25, 2021. Contact Sara Albertson; FSSA, Office of Medicaid Policy and Planning; 317-233-4455; spacomment@fssa.in.gov

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2021-06-04T13:07:37-04:00June 4, 2021|Indiana|

Iowa

The Board of Pharmacy released a response to the Governor’s new Proclamation of Disaster Emergency issued on May 27, extending much of the pharmacy practice regulatory relief. The suspension of regulatory provisions identified in the Proclamation is effective through June 26, 2021, unless otherwise extended or terminated by Gov. Kim Reynolds (R). Please note the suspension of Iowa Code § 155A.32 to allow a pharmacist to engage in therapeutic drug product substitution, according to Board guidance, should not be expected to be further extended.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-06-04T13:06:21-04:00June 4, 2021|Iowa|

Maryland

Effective May 30, due to the enactment of HB 135 pharmacists may administer certain injectable maintenance medications. The bill was sponsored by Del. Karen Lewis Young (D) and specifically includes drugs for psychiatric disorders, substance abuse, contraception, and vitamins. NACDS assisted in the efforts of both the Maryland Pharmacists Association and the Maryland Association of Chain Drug Stores in supporting this measure.

Also in Maryland, Gov. Hogan (R) signed SB 537, a bill that requires pharmacists to inform patients of lower-cost alternative drugs if the information is readily available. It will also permit pharmacists to interchange a less expensive brand-name drug that is therapeutically equivalent to the prescribed drug under certain conditions. The bill will be effective October 1, 2021; however, the Board of Pharmacy is required to promulgate regulations for certain provisions of the legislation.

Also in Maryland, the Board of Pharmacy recently shared that they will be reaching out to about 1200 pharmacists in Maryland who need to register with the Prescription Drug Monitoring Program (PDMP). To register, click here.  For further information about registering see the Board’s FAQ.

Also in Maryland, the Department of Health has renewed its standing order allowing the dispensing of naloxone without a prescription. The order will remain in effect until June 1, 2023.

Lastly in Maryland, the Maryland Association of Chain Drug Stores (MACDS) is seeking a pharmacist to serve on the Maryland Pharmacy Coalition Scope of Practice and Reimbursement Task Force. You can review the minutes from their most recent monthly meeting here. Please contact Jill McCormack if you are interested in participating.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2021-06-04T13:03:36-04:00June 4, 2021|Maryland|
Go to Top